Spotlight on dabrafenib/trametinib in the treatment of non-small-cell lung cancer: place in therapy

References

• ReckMPopatSReinmuthNMetastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnn Oncol201425Suppl 3iii27iii3925115305
   PubMed Web of Science ®Google Scholar
• WakeleeHAChangETGomezSLLung cancer incidence in never smokersJ Clin Oncol200725547247817290054
   PubMed Web of Science ®Google Scholar
• StewartBWWildCPWorld Cancer Report 2014Lyon, FranceInternational Agency for Research on Cancer2014
   Google Scholar
• SEER Research Data 1973-2014 – ASCII Text Data: Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) Research Data (1973-2014)National Cancer Institute, DCCPS, Surveillance Research Program released April 2017 based on the November 2016 submission
   Google Scholar
• MolinaJRYangPCassiviSDSchildSEAdjeiAANon-small cell lung cancer: epidemiology, risk factors, treatment, and survivorshipMayo Clin Proc200883558459418452692
   PubMed Web of Science ®Google Scholar
• SandlerABNemunaitisJDenhamCPhase III trial of gemcitabine plus cisplatin vs cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancerJ Clin Oncol200018112213010623702
   PubMed Web of Science ®Google Scholar
• GatzemeierUvon PawelJGottfriedMPhase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small cell lung cancerJ Clin Oncol200018193390339911013280
   PubMed Web of Science ®Google Scholar
• Von PawelJvon RoemelingRGatzemeierUTirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: a report of the International CATAPULT 1 Study Group. Cisplatin and tirapazamine in subjects with advanced previously untreated non-small-cell lung tumorsJ Clin Oncol20001861351135910715308
   PubMed Web of Science ®Google Scholar
• LeChevalierTBrisgandDDouillardJYRandomised study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in non-small-cell lung cancer. Results of an European multicenter trial including 612 patientsJ Clin Oncol19941223603678113844
   PubMed Web of Science ®Google Scholar
• BonomiPKimKChangAJohnsonDPhase III trial comparing etoposide/cisplatin versus taxol with cisplatin G-CSF versus taxol/cisplatin in advanced non-small cell lung cancer [abstract 1145]Proc Am Soc Clin Oncol199615382
   Google Scholar
• HuangTKarsyMZhugeJZhongMLiuDB-Raf and the inhibitors: from bench to bedsideJ Hematol Oncol201363023617957
   PubMed Web of Science ®Google Scholar
• TuvesonDAWeberBLHerlynMBRAF as a potential therapeutic target in melanoma andother malignanciesCancer Cell200342959812957284
   PubMed Web of Science ®Google Scholar
• ChongHVikisHGGuanKLMechanisms of regulating the Raf kinase familyCell Signal200315546346912639709
   PubMed Web of Science ®Google Scholar
• SchaefferHJWeberMJMitogen-activated protein kinases: specific messages from ubiquitous messengersMol Cell Biol19991942435244410082509
   PubMed Web of Science ®Google Scholar
• NazarianRShiHWangQMelanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulationNature2010468732697397721107323
   PubMed Web of Science ®Google Scholar
• TiacciETrifonovVSchiavoniGBRAF mutations in hairy-cell leukemiaN Engl J Med2011364242305231521663470
   PubMed Web of Science ®Google Scholar
• DaviesHBignellGRCoxCMutations of the BRAF gene in human cancerNature2002417689294995412068308
   PubMed Web of Science ®Google Scholar
• FaginJAMitsiadesNMolecular pathology of thyroid cancer: diagnostic and clinical implicationsBest Pract Res Clin Endocrinol Metab200822695596919041825
   PubMed Web of Science ®Google Scholar
• LinCCLinJKLinTCThe prognostic role of microsatellite instability, codon-specific KRAS, and BRAF mutations in colon cancerJ Surg Oncol2014110445145724964758
   PubMed Web of Science ®Google Scholar
• HolderfieldMDeukerMMMcCormickFMcMahonMTargeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyondNat Rev Cancer201414745546724957944
   PubMed Web of Science ®Google Scholar
• FiskusWMitsiadesNB-Raf inhibition in the clinic: present and futureAnnu Rev Med201667294326768236
   PubMed Web of Science ®Google Scholar
• CuiGLiuDA meta-analysis of the association between BRAF mutation and nonsmall cell lung cancerMedicine20179614e655228383426
   PubMed Web of Science ®Google Scholar
• TissotCCouraudSTanguyRBringuierPPGirardNSouquetPJClinical characteristics and outcome of patients with lung cancer harboring BRAF mutationsLung Cancer201691232826711930
   PubMed Web of Science ®Google Scholar
• BallantyneADGarnock-JonesKPDabrafenib: first global approvalDrugs201373121367137623881668
   PubMed Web of Science ®Google Scholar
• LaquerreSArnoneMMossKAbstract B88: a selective Raf kinase inhibitor induces cell death and tumor regression of human cancer cell lines encoding B-Raf V600E mutationMol Cancer Ther2009812 SupplB88
   Web of Science ®Google Scholar
• HauschildAGrobJJDemidovLVDabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trialLancet2012380983935836522735384
   PubMed Web of Science ®Google Scholar
• HauschildAGrobJJDemidovLVAn update on BREAK-3, a phase III, randomized trial: dabrafenib (DAB) versus dacarbazine (DTIC) in patients with BRAF V600E-positive mutation metastatic melanoma (MM)J Clin Oncol20133115 Suppl90139013
   Web of Science ®Google Scholar
• ChanMHayduLMenziesAMClinical characteristics and survival of BRAF-mutant (BRAF plus) metastatic melanoma patients (pts) treated with BRAF inhibitor (BRAFi) dabrafenib or vemurafenib beyond disease progression (PD)J Clin Oncol20133115 Suppl90629062
   Web of Science ®Google Scholar
• ShiHHugoWKongXAcquired resistance and clonal evolution in melanoma during BRAF inhibitor therapyCancer Discov201441809324265155
   PubMed Web of Science ®Google Scholar
• WrightCJMcCormackPLTrametinib: first global approvalDrugs201373111245125423846731
   PubMed Web of Science ®Google Scholar
• FlahertyKTRobertCHerseyPImproved survival with MEK inhibition in BRAF-mutated melanomaN Engl J Med2012367210711422663011
   PubMed Web of Science ®Google Scholar
• KimKKeffordRPavlickACPhase II study of the MEK1/MEK2 inhibitor trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitorJ Clin Oncol201331448248923248257
   PubMed Web of Science ®Google Scholar
• FlahertyKTInfanteJRDaudACombined BRAF and MEK inhibition in melanoma with BRAF V600 mutationsN Engl J Med2012367181694170323020132
   PubMed Web of Science ®Google Scholar
• LongGVStroyakovskiyDGogasHCombined BRAF and MEK inhibition versus BRAF inhibition alone in melanomaN Engl J Med2014371201877188825265492
   PubMed Web of Science ®Google Scholar
• PratilasCAHanrahanAJHalilovicEGenetic predictors of MEK dependence in non-small cell lung cancerCancer Res200868229375938319010912
   PubMed Web of Science ®Google Scholar
• JoshiMRiceSJLiuXMillerBBelaniCPTrametinib with or without vemurafenib in BRAF mutated non-small cell lung cancerPLoS One2015102e011821025706985
   PubMed Web of Science ®Google Scholar
• GautschiOPauliCStrobelKA patient with BRAF V600E lung adenocarcinoma responding to vemurafenibJ Thorac Oncol2012710e23e2422743296
   PubMed Web of Science ®Google Scholar
• SchmidaSSianoaMJoergerMRodriguezRMüllerJFrühMCase report: response to dabrafenib after progression on vemurafenib in a patient with advanced BRAF V600E-mutant bronchial adenocarcinomaLung Cancer2015871858725466451
   PubMed Web of Science ®Google Scholar
• PlanchardDKimTMMazieresJDabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trialLancet Oncol201617564265027080216
   PubMed Web of Science ®Google Scholar
• PlanchardDBesseBGroenHJMDabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trialLancet Oncol201617798499327283860
   PubMed Web of Science ®Google Scholar
• PlanchardDSmitEGroenHJMDabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trialLancet Oncol201718101307131628919011
   PubMed Web of Science ®Google Scholar
• PervereLMRakshitSSchrockABMillerVAAliSMVelchetiVDurable response to combination of dabrafenib and trametinib in BRAF V600E-mutated non-small-cell lung cancerClin Lung Cancer2017183e211e21328024926
   PubMed Web of Science ®Google Scholar